Long-Term Stability of Glycopyrrolate Oral Solution Galenic Compound at Different Storage Conditions
Pharmaceutics · 31.07.2024 · 16 (8) · 1018
DOI: 10.3390/pharmaceutics16081018 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 31.07.2024. Verfasst von Barbara Bellich und 11 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Maternal and Child Health, IRCCS "Burlo Garofolo", Via dell'Istria 65/1, 34137 Trieste, Italy. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero della Salute, THE MINISTRY OF HEALTH.
Abstract (Originalsprache)
Glycopyrrolate is a competitive muscarinic receptor antagonist used in the treatment of sialorrhea, especially in pediatrics. Degradation research was conducted to better understand the stability of the active pharmaceutical ingredient (API). Using an HPLC-UV method, we evaluated the chemical stability of the oral solution of the galenic compound glycopyrrolate 0.5 mg/mL under different storage conditions. Method validation was performed according to the International Council for Harmonization (ICH) Q2(R2) guidelines. The results of the stability study of the galenic compound in different storage conditions, with the exception of those stored in glass containers at 45 °C for more than 3 months, were stable (100 ± 10% of the nominal concentration). The aim of this work was to study the stability of the galenic compound glycopyrrolate in two different types of containers and at three different storage temperatures. Glycopyrrolate showed degradation beyond the limits only in glass at 45 °C and after 2 months of storage. The results indicate that oral liquid dosage forms of glycopyrrolate are stable for at least 210 days when stored at room temperature or at 4 °C, in glass or PET, for at least 7 months, maintaining product quality according to the standards established by the European Pharmacopoeia, ensuring long-term coverage for pediatric patient therapies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute for Maternal and Child Health, IRCCS "Burlo Garofolo", Via dell'Istria 65/1, 34137 Trieste, Italy.
- Department of Medical, Surgical and Health Sciences, University of Trieste, 34149 Trieste, Italy.
- Department of Chemical and Pharmaceutical Sciences, University of Trieste, Via L. Giorgieri 1, 34127 Trieste, Italy.
ORCID-Profile: Barbara Bellich, Debora Curci, Mario Cirino, Gianpiero Adami, Natalia Maximova, Egidio Barbi, Davide Zanon
Förderung
- Ministero della Salute
- THE MINISTRY OF HEALTH
Zitieren
APA
Bellich, B., Franzin, M., Curci, D., Cirino, M., Maestro, A., Bennati, G., Stocco, G., Adami, G., Maximova, N., Grasso, D. L., Barbi, E., & Zanon, D. (2024). Long-Term Stability of Glycopyrrolate Oral Solution Galenic Compound at Different Storage Conditions. Pharmaceutics, 16(8), 1018. https://doi.org/10.3390/pharmaceutics16081018
Vancouver
Bellich B, Franzin M, Curci D, Cirino M, Maestro A, Bennati G, et al. Long-Term Stability of Glycopyrrolate Oral Solution Galenic Compound at Different Storage Conditions. Pharmaceutics. 2024;16(8):1018. doi:10.3390/pharmaceutics16081018
BibTeX
@article{Bellich2024,
author = {Bellich, Barbara and Franzin, Martina and Curci, Debora and Cirino, Mario and Maestro, Alessandra and Bennati, Giada and Stocco, Gabriele and Adami, Gianpiero and Maximova, Natalia and Grasso, Domenico Leonardo and Barbi, Egidio and Zanon, Davide},
title = {Long-Term Stability of Glycopyrrolate Oral Solution Galenic Compound at Different Storage Conditions},
journal = {Pharmaceutics},
year = {2024},
volume = {16},
number = {8},
pages = {1018},
doi = {10.3390/pharmaceutics16081018}
}
EUVIMED